BSE filing, NSE: VENMAX. Summary written from the filing by ALFA Finder's alert engine.
Venmax Drugs & Pharmaceuticals Ltd: key numbers
- Share price
- ₹13.39
- Market cap
- ₹11.76 Cr
- Revenue (annual)
- ₹8.02 Cr
- Net profit (annual)
- ₹0.25 Cr
- P/E (TTM)
- 42.0×Sector 45.9×
- Promoter holding
- 10.46%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Venmax Drugs & Pharmaceuticals Ltd
All →Venmax Drugs & Pharmaceuticals Acquisition
Venmax Drugs' shareholders met on 24 October 2026 under an NCLT order to approve an amalgamation with Hatri Pharma. Voting results await the scrutinizer's report.
Venmax Drugs & Pharmaceuticals Other Announcement
The company filed its quarterly shareholding pattern under Regulation 31(1)(b) of the SEBI LODR Regulations for the quarter ended September 30, 2026.
Venmax Drugs & Pharmaceuticals Annual General Meeting
Venmax Drugs and Pharmaceuticals held its 37th Annual General Meeting on September 26, 2026. Shareholders considered the financial statements and various directorship appointments.
Venmax Drugs & Pharmaceuticals Acquisition
Venmax Drugs and Pharmaceuticals Limited announced an NCLT-convened meeting of equity shareholders on October 24, 2026, to consider the proposed merger with Hatri Pharma Private Limited.
Venmax Drugs & Pharmaceuticals Acquisition
NCLT Hyderabad directed Venmax to convene a shareholder meeting on 24 Oct 2026 for the amalgamation of Hatri Pharma into Venmax. The order also dispensed with meetings of Hatri Pharma's shareholders and creditors.
Venmax Drugs & Pharmaceuticals Board Meeting Outcome
Venmax Drugs held a board meeting to approve the Directors' Report, AGM date, and appoint/regularize key directors. The meeting outcomes were disclosed under Regulation 30.
Other annual report announcements
All →Datakosa Annual Report
Bodhtree Consulting filed its 44th Annual Report for FY 2025-26 with the AGM notice for September 9, 2026. It reports no new transaction or financial event.
Morarka Finance Annual Report
Morarka Finance filed its 2025-26 Annual Report and AGM notice for the July 15, 2026 meeting. Agenda includes Pranay Morarka's Managing Director appointment and remuneration.
Venlon Enterprises Annual Report
Venlon Enterprises filed its 2025-26 Annual Report ahead of its September 18, 2026 AGM. The notice seeks approval for three related-party transactions.
Gujarat Peanut and Agri Products Annual Report
Gujarat Peanut And Agri Products filed a resubmitted Annual Report for FY 2025-26 after an earlier filing went under the wrong module. The report shows turnover of Rs. 38,932.71 Lakhs and PAT of Rs. 738.30 Lakhs.
Patel Chem Specialities Annual Report
Patel Chem Specialities filed its Annual Report for FY2025-26, covering corporate overview, product suite and company profile pages. The filing is a full annual report with no discrete transaction or event.
Bhavik Enterprises Annual Report
Bhavik Enterprises rectifies an error in Notes 3.3 and 3.4 of its FY2025-26 audited financial statements. Promoter holdings were overstated by 10,00,000 shares that were sold in the IPO offer for sale.